ENANTA PHARMACEUTICALS INC's ticker is ENTA and the CUSIP is 29251M106. A total of 150 filers reported holding ENANTA PHARMACEUTICALS INC in Q3 2021. The put-call ratio across all filers is - and the average weighting 0.2%.
Quarter-by-quarter ownership
Value | Shares | Weighting | ||||
---|---|---|---|---|---|---|
Q3 2021 | $880,000 | +10.6% | 15,489 | -14.4% | 0.05% | +14.0% |
Q2 2021 | $796,000 | -18.2% | 18,091 | -8.3% | 0.04% | -23.2% |
Q1 2021 | $973,000 | +19.4% | 19,724 | +1.8% | 0.06% | -5.1% |
Q4 2020 | $815,000 | -59.5% | 19,366 | -55.9% | 0.06% | -9.2% |
Q3 2020 | $2,010,000 | -64.2% | 43,902 | -60.7% | 0.06% | -55.2% |
Q2 2020 | $5,612,000 | -13.0% | 111,769 | -10.9% | 0.14% | -14.7% |
Q1 2020 | $6,453,000 | -24.3% | 125,472 | -9.1% | 0.17% | +41.7% |
Q4 2019 | $8,524,000 | +3757.0% | 137,980 | +3647.4% | 0.12% | +3900.0% |
Q3 2019 | $221,000 | -57.0% | 3,682 | -39.6% | 0.00% | -70.0% |
Q2 2019 | $514,000 | +18.2% | 6,095 | +33.8% | 0.01% | +11.1% |
Q1 2019 | $435,000 | +75.4% | 4,556 | +30.1% | 0.01% | +80.0% |
Q4 2018 | $248,000 | -38.0% | 3,502 | -25.1% | 0.01% | -37.5% |
Q3 2018 | $400,000 | -91.8% | 4,677 | -88.9% | 0.01% | -93.5% |
Q2 2018 | $4,869,000 | +1161.4% | 42,007 | +779.5% | 0.12% | +1027.3% |
Q1 2018 | $386,000 | – | 4,776 | – | 0.01% | – |
Download |
Other shareholders
Name | Shares | Value | Weighting ↓ |
---|---|---|---|
Krensavage Asset Management, LLC | 476,042 | $45,472,000 | 12.29% |
Stonepine Capital Management, LLC | 60,840 | $5,811,000 | 3.34% |
ACUTA CAPITAL PARTNERS, LLC | 61,000 | $5,827,000 | 2.77% |
Virtus ETF Advisers LLC | 10,634 | $1,016,000 | 2.16% |
INTERNATIONAL BIOTECHNOLOGY TRUST PLC | 61,000 | $5,827,000 | 2.15% |
ARMISTICE CAPITAL, LLC | 372,000 | $35,533,000 | 1.94% |
Matarin Capital Management, LLC | 209,403 | $20,002,000 | 1.46% |
Monashee Investment Management LLC | 50,000 | $4,776,000 | 1.10% |
Granahan Investment Management | 151,322 | $14,454,000 | 0.78% |
ALGERT GLOBAL LLC | 13,186 | $1,260,000 | 0.72% |